In this exclusive conversation, Sakshi Batra speaks with Dr. Habil Khorakiwala, Founder Chairman of Wockhardt Group, as the company prepares to file an application for its new drug Zaynich with the USFDA next week. However, the recent imposition of 100% tariffs on certain pharma imports has created new challenges. Dr. Khorakiwala confirms that Wockhardt is not currently manufacturing in the US, but the company is exploring alternative strategies — including licensing agreements and contract manufacturing within the US — to sidestep tariff barriers without setting up a new facility. He also sheds light on the broader landscape: while Indian pharmaceutical companies dominate the generics space in the US, very few export branded drugs. Despite trade obstacles, the US remains the largest expor

See Full Page